10-K: VitaSpring Biomedical Reports $4.16M Loss, Seeks Funding

VitaSpring Biomedical Co. Ltd. reported a net loss of $4.16 million for the fiscal year ended January 31, 2023, a significant decline from the prior year's profit, as it focuses on R&D and seeks additional capital.

Summary

• VitaSpring Biomedical is a development-stage company focused on research, development, and commercialization of products promoting wellness and a healthy lifestyle, specializing in cellular and regenerative medicine.
• The company reported no revenue for the fiscal year ended January 31, 2023, a substantial decrease from $5,613,200 in fiscal year 2022.
• A net loss of $4,164,396 was recorded for fiscal year 2023, a significant reversal from the net income of $909,560 in fiscal year 2022.
• Cash and cash equivalents decreased to $29,656 as of January 31, 2023, from $107,212 in the prior year.
• Management believes current cash resources are insufficient to fund operations for the next twelve months and that additional capital is required.
• A material weakness in internal control over financial reporting was identified due to inadequate segregation of duties and insufficient accounting personnel.
• The company's former officers and director (Pao-Chi Chu, Cheng-Hsiang Kao, Jer-Li Lin, Yen Xun Chen) resigned effective August 15, 2024, and Ms. Ssu-Chuan Lai was appointed as the sole director and executive officer effective August 7, 2025.
• The Annual Report on Form 10-K for the fiscal year ended January 31, 2023, was filed after its original due date, and the company is working to regain full compliance with periodic reporting obligations.

Sentiment

Score: 2

Explanation: The company reported a complete cessation of revenue and a substantial net loss, moving from profitability to a significant deficit. It faces critical liquidity issues, with current cash insufficient to fund operations for the next 12 months, leading to a going concern warning. Material weaknesses in internal controls and a lack of formal cybersecurity policies indicate significant operational and governance risks. While there's a new CEO and long-term R&D goals, the immediate financial and operational challenges are severe, making it a high-risk investment with a strong likelihood of further value erosion without substantial, uncertain capital infusion.

Positives

• Possesses proprietary technical know-how related to cell culture, purification, and expansion processes that may enhance exosome yield and cell viability.
• Utilizes ethical sourcing protocols that employ non-embryonic human placental tissue.
• Maintains strategic relationships in Asia, a region recognized for leadership in regenerative medicine and cell-therapy innovation.
• Has a long-term objective to establish a Good Tissue Practice (GTP)-compliant cell-production and storage facility to support future research and clinical applications.
• The research and development team has received multiple Taiwan National Innovation Awards (2019-2021).
• The new CEO, Ssu-Chuan Lai, Ph.D., brings over a decade of experience in biomedical research, clinical rehabilitation, and cell manufacturing operations, including leading a GTP/GMP-compliant cell manufacturing center.

Negatives

• Generated no revenue during the fiscal year ended January 31, 2023, a significant decline from $5,613,200 in the prior year.
• Recorded a net loss of $4,164,396 for fiscal year 2023, compared with a net income of $909,560 for fiscal year 2022.
• Incurred a gross loss of $3,333,000 for fiscal year 2023, a reversal from a gross profit of $2,068,000 in fiscal year 2022.
• Cash and cash equivalents decreased by approximately $77,500 to $29,656 as of January 31, 2023.
• Has an accumulated deficit of $3,388,019 and negative cash flow from operations of $77,556, raising substantial doubt about the ability to continue as a going concern.
• Current cash resources are insufficient to fund operations for the next twelve months without additional capital.
• Identified a material weakness in internal control over financial reporting due to inadequate segregation of duties and insufficient accounting personnel.
• Does not have a formal, written cybersecurity risk management policy or enterprise-wide cybersecurity governance framework as of the filing date.
• Former officers and director are subject to civil and criminal legal proceedings in Taiwan concerning unauthorized use or disclosure of business know-how and intellectual property.
• Experienced 100% customer concentration in fiscal year 2022 and 100% vendor concentration in fiscal years 2023 and 2022, posing significant business risks.
• The annual report was filed after its original due date.
• Did not conduct any research and development (R&D) activities or incur R&D expenses during fiscal years ended January 31, 2023 and 2022, due to lack of sufficient funding.
• Does not own or hold any issued patents, registered trademarks, or other registered intellectual property rights.
• Public trading in common stock is very limited, with minimal volume and no consistent bid or ask quotations, making it difficult for investors to buy or sell shares.

Risks

• Ability to develop, commercialize, and market functional-medicine and nutraceutical formulations.
• Dependence on third-party research, manufacturing, and supply partners.
• Ability to raise additional capital to fund operations.
• Competition within the biomedical and nutraceutical industries from companies with significantly greater financial, technical, and research resources.
• Loss of key personnel or inability to attract qualified employees and consultants.
• Regulatory approvals, compliance costs, and potential changes in applicable laws.
• Disruptions in supply chains or research partnerships.
• Economic, geopolitical, and market conditions.
• Inadequacy of insurance coverage for certain losses or liabilities.
• Potential asset impairments or other non-cash charges.
• Substantial doubt about the ability to continue as a going concern due to accumulated deficit and negative cash flow.
• Lack of a formal cybersecurity risk management framework may expose the company to vulnerabilities.
• Legal proceedings involving former officers and director, potentially leading to reputational harm or operational impacts.
• Reliance on a single vendor for 100% of purchases, which could have a negative impact if the vendor is lost.
• Limited public trading in common stock, making it difficult for investors to buy or sell shares at desired prices.
• Additional issuances of equity or convertible debt securities will result in dilution to current shareholders.

Future Outlook

Management plans to explore and implement R&D programs once sufficient funding becomes available, focusing on scientific validation, process optimization, and regulatory readiness for its X.msc mesenchymal stem-cell platform and exosome-based formulations. The company anticipates X.msc-based projects will progress to limited hospital implementation within approximately five years and intends to establish a U.S. FDA-regulated stem cell bank. Future R&D will emphasize stem-cell isolation and expansion, exosome production and characterization, formulation and product development, and process automation and quality control aligned with GTP and GMP principles. The company expects to require additional capital to fund operations and growth, planning to seek equity or debt financing and strategic partnerships. A formal cybersecurity risk assessment and governance policy is intended to be implemented by Q1 2026, and a Code of Business Conduct in 2025. The company also plans to recruit key personnel and consider appointing independent directors as operations expand.

Management Comments

• "We are currently focusing on restructuring our product strategy and developing long-term partnerships rather than pursuing short-term sales."
• "We continue to carefully manage overhead while maintaining core research and corporate functions."
• "Management believes that additional capital will be required to support operations over the next twelve months."
• "Management is exploring potential sources of financing, including private placements of equity or debt securities and strategic partnerships."
• "We believe our current cash resources will not be sufficient to fund planned operations for the next twelve months without additional capital."
• "The continuation of our business depends on our ability to raise funds and generate future revenue."
• "Management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses."
• "Management will continue to monitor the situation and assess any implications on the Company's leadership or its operations." (Regarding legal proceedings of former officers)
• "We are committed to improving our internal control environment." (Regarding material weakness)

Industry Context

VitaSpring Biomedical operates within the rapidly growing global regenerative-medicine and functional-wellness industry, which combines advances in cell biology, biotechnology, and preventive health. The regenerative-medicine market exceeded $25 billion in 2024 and is projected to continue expanding. Key industry trends include the growth of cell-based therapies, a shift towards preventive and personalized medicine, evolving regulatory frameworks, the integration of biotechnology and aesthetics, and the leadership of Asia-Pacific countries in stem-cell innovation. The industry is highly fragmented and competitive, with VitaSpring facing competition from early-stage research companies, established biotechnology firms, and university-affiliated laboratories, many of which possess significantly greater resources.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Former Chief Executive Officer, Mr. Cheng-Hsiang Kao, and Chairman of the Board, Mr. Pao-Chi Chu, are involved in civil and criminal legal proceedings in Taiwan.
• The proceedings involve allegations concerning the unauthorized use or disclosure of business know-how and intellectual property.
• The company is not a named party in these proceedings.
• Management has concluded that these matters are not expected to have a material adverse effect on the company's financial condition or results of operations as of the balance sheet date, but will continue to monitor the situation.

Related Party Transactions

• Advances from related party: The company received advances totaling $94,358 from Cheng-Hsiang Kao (previous CEO and major shareholder) during the year ended January 31, 2022. Total outstanding advances from related party were $214,682 as of January 31, 2023, and $94,358 as of January 31, 2022. These advances are unsecured, non-interest bearing, and payable on demand.
• Due to related party: The company sources its inventory exclusively from a vendor wholly owned by shareholders who collectively hold more than 20% of the company's outstanding common shares and are family members of the former Chairman. Amounts due to this related party totaled $2,411,000 as of January 31, 2023, and $1,251,500 as of January 31, 2022.

Stakeholder Impact

• Shareholders: Face significant dilution risk from potential future equity issuances, limited public trading makes selling shares difficult, no dividends are expected, and there is substantial doubt about the company's ability to continue as a going concern.
• Employees/Consultants: Operations are currently conducted by a network of contractors and consultants; plans exist to expand the organization by hiring key personnel in R&D, quality assurance, regulatory affairs, and business development once sufficient funding becomes available.
• Customers: Currently, no products or treatments are sold for consumer use; future efforts are focused on research and development, with an anticipated business-to-business (B2B) model serving institutional and clinical clients.
• Suppliers: The company has high reliance on a single related-party vendor, which supplied 100% of total purchases in fiscal years 2023 and 2022, posing a significant risk if this vendor relationship is lost.
• Creditors: The company has significant related-party payables and advances, and the going concern uncertainty raises concerns about its ability to meet future obligations.

Next Steps

• Regain full compliance with periodic reporting obligations under the Securities Exchange Act of 1934.
• Explore and implement R&D programs once sufficient funding becomes available.
• Refine methods for isolating and expanding X.msc cells derived from ethically sourced, non-embryonic human placental tissue.
• Develop scalable methods to increase the yield and quality of exosomes.
• Design prototype formulations combining exosome and redox-balance research for potential topical, injectable, or nutraceutical uses.
• Implement standardized production protocols aligned with Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) principles.
• Collaborate with academic institutions, hospitals, and affiliated research companies in Taiwan and other Asia-Pacific regions.
• Engage external contract research organizations (CROs) for specialized testing and validation services.
• Pursue intellectual property protection through patent and trademark filings once product candidates and technologies reach a more advanced stage of development.
• Implement data protection and cybersecurity measures to ensure compliance with applicable privacy and data security regulations.
• Establish a U.S. FDA-regulated stem cell bank capable of supplying ready-to-use allogeneic MSCs.
• Expand the organization by hiring key personnel in research and development, quality assurance, regulatory affairs, and business development.
• Evaluate and enhance internal control procedures and, as resources permit, hire additional qualified personnel or engage external consultants with relevant expertise in financial reporting and SEC compliance.
• Implement a formal cybersecurity risk assessment and governance policy by Q1 2026.
• Adopt a Code of Business Conduct in 2025.
• Evaluate the formation of appropriate Board committees and consider appointing one or more independent directors in the future.
• Seek additional equity or debt financing and pursue strategic partnerships or licensing opportunities to meet capital needs.

Key Dates

Recommendation

The company reported a complete cessation of revenue and a substantial net loss, moving from profitability to a significant deficit. It faces critical liquidity issues, with current cash insufficient to fund operations for the next 12 months, leading to a going concern warning. Material weaknesses in internal controls and a lack of formal cybersecurity policies indicate significant operational and governance risks. The stock has very limited trading volume, making it illiquid. While there's a new CEO and long-term R&D goals, the immediate financial health and operational risks are severe, making it a high-risk investment with a strong likelihood of further value erosion without substantial, uncertain capital infusion.

Keywords

Regenerative Medicine, Stem Cells, Exosomes, Biotechnology, Nutraceuticals, Biomedical, Cell Therapy, Functional Wellness, X.msc, SEC Filing, 10-K, Development Stage, Taiwan National Innovation Awards, GTP, GMP, FDA